Arcturus, Ultragenyx ally in rare disease pact worth up to $1.6bn; deal expanded
Executive Summary
RNA-focused start-up Arcturus Therapeutics Inc. (ATI) and fellow rare disease therapeutics developer Ultragenyx Pharmaceutical Inc. will collaborate on the discovery and development of messenger RNA (mRNA) therapeutics for up to ten select undisclosed rare disease targets, using Arcturus' UNA (Unlocked Nucleomonomer Agent) and LUNAR enabling technologies.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice